SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending following reports that Trump is considering reclassifying marijuana, a move seen as a major catalyst for the cannabis industry. The community is buzzing about potential rallies and short squeezes, with many anticipating significant gains. Discussions also include the potential impact on other cannabis stocks and the broader implications for the sector.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending due to a mixed reaction to its earnings report; despite beating expectations and providing strong AI revenue guidance, the stock dipped as investors focused on margin concerns and a lack of specific long-term outlook. The community is debating whether this pullback is a buying opportunity or a sign of broader AI sector concerns, with many analysts reiterating bullish price targets amid the selloff.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to community discussion around its cancer treatment pipeline, particularly after positive data in prostate cancer trials, leading to speculation about potential partnerships or a buyout. Investors believe the company is undervalued, with a high short interest creating potential for a short squeeze. The community is focused on the upcoming catalysts and continued data releases.

Jiuzi Holdings, Inc. engages in franchise and operation of retail stores. The firm sells new energy vehicles (NEVs) under the brand name Jiuzi. It operates through the NEVs Sales and Franchise Services segments. The company was founded on October 10, 2019 and is headquartered in Hangzhou, China.

Jiuzi Holdings Inc

Jiuzi Holdings is trending due to news surrounding a significant commitment to expand its private placement to $1 billion, sparking discussion about potential for high gains. However, the community is also wary, with some users labeling the stock a "scam" and expressing concerns about Chinese stocks in general and potential dilution. Some traders are looking at similar stocks, hoping for a related sympathy run.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst ($BCRX) is trending as traders discuss the potential impact of the upcoming FDA decision on Orladeyo for pediatric patients, with some anticipating a revenue boost while others believe it's already priced in. Community members are actively debating the stock's valuation, short interest, and the potential for a buyback program to drive the price higher. The acquisition of Astria Therapeutics and the departure of a board member are also being considered as factors influencing the stock's future performance.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon's stock is trending after a surprising announcement that CEO Calvin McDonald will step down, coupled with better-than-expected quarterly results. The community is actively discussing the potential implications of this leadership change, along with the company's growth strategy and the impact of tariffs on margins. Investors are also reacting positively to the approval of a $1 billion increase to the stock repurchase program.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

FRMI is trending due to a significant drop following the termination of an agreement with its first tenant, sparking concerns about the company's data center project and future prospects; however, some investors believe the market overreacted, citing the long-term potential of AI-driven infrastructure and the company's ongoing negotiations for new tenants, while others are calling the company a scam. Community members are actively discussing potential entry points, short borrow availability, and speculating on the identity of the tenant that cancelled the agreement.

Katapult Holdings, Inc. is an e-commerce focused financial technology company. The firm is engaged in the provision of e-commerce point-of-sale lease-purchase options for nonprime U.S. consumers. It offers its customers a lease purchase transaction processing system with no long-term obligation and options for ownership. The company was founded in August 2019 and is headquartered in Plano, TX.

Katapult Holdings Inc

KPLT is trending amid discussions about a potential merger and its impact on shareholder value, as well as ongoing speculation around a possible short squeeze. Community members are actively debating the company's value after a proposed all-stock transaction and analyzing its potential for growth. The stock is also experiencing high volatility and unusual trading volume, prompting discussions about potential catalysts and market manipulation.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as investors discuss whether it can challenge previous highs amid a rally in precious metals; the community debates the factors driving gold's performance, including central bank policy, geopolitical tensions, and its role as a safe haven. Some are pointing to silver's outperformance as a signal, while others eye potential pullbacks.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5,769,230 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Vivo Capital LLC

Vivo Capital LLC bought a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat reports. One...

Franklin Resources Inc. Invests $13.10 Million in CytomX Therapeutics, Inc. $CTMX

Franklin Resources Inc. bought a new stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities...

CytomX Therapeutics (NASDAQ:CTMX) Trading Down 7.1% - Here's Why

CytomX Therapeutics (NASDAQ:CTMX) Trading Down 7.1% - Here's Why...

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Down - Should You Sell?

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Down - What's Next...

What is HC Wainwright's Forecast for CTMX FY2025 Earnings?

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Investment analysts at HC Wainwright decreased their FY2025 earnings estimates for CytomX Therapeutics in a research note issued to investors...

CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $10.00

HC Wainwright boosted their target price on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the company a "buy" rating in a report on Tuesday...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 12% - Time to Buy?

CytomX Therapeutics (NASDAQ:CTMX) Shares Up 12% - Here's Why...

CytomX Therapeutics (NASDAQ:CTMX) Earns Outperform Rating from Wedbush

Wedbush reissued an "outperform" rating and set a $6.00 price objective on shares of CytomX Therapeutics in a research report on Friday...

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Down After Earnings Miss

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Down on Disappointing Earnings...

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CTMX News

CTMXCytomX Therapeutics Inc